School of Optometry, Aston University, Birmingham, UK.
University of Houston, College of Optometry, Houston, TX, USA.
Eye (Lond). 2024 Feb;38(3):455-463. doi: 10.1038/s41433-023-02723-5. Epub 2023 Sep 22.
A range of optical interventions have been developed to slow the progression of myopia. This review summarizes key studies and their outcomes. Peer-reviewed, randomized controlled clinical trials of at least 18 months duration were identified. Randomized clinical trials were identified and summarised: 13 for spectacles, 5 for overnight orthokeratology, 5 for soft contact lenses, and 3 for orthokeratology combined with low concentration atropine. Overnight orthokeratology trials were the most consistent with 2-year slowing of axial elongation between 0.24 and 0.32 mm. Other modalities were more variable due to the wide range of optical designs. Among spectacle interventions, progressive addition lenses were the least effective, slowing axial elongation and myopia progression by no more than 0.11 mm and 0.31 D, respectively. In contrast, novel designs with peripheral lenslets slow 2-year elongation and progression by up to 0.35 mm and 0.80 D. Among soft contact lens interventions, medium add concentric bifocals slow 3-year elongation and progression by only 0.07 mm and 0.16 D, while a dual-focus design slows 3-year elongation and progression by 0.28 mm and 0.67 D. In summary, all three optical interventions have the potential to significantly slow myopia progression. Quality of vision is largely unaffected, and safety is satisfactory. Areas of uncertainty include the potential for post-treatment acceleration of progression and the benefit of adding atropine to optical interventions.
已经开发出一系列光学干预措施来减缓近视的进展。本综述总结了关键研究及其结果。确定了至少持续 18 个月的同行评审、随机对照临床试验。确定并总结了随机临床试验:13 项用于眼镜,5 项用于过夜角膜塑形术,5 项用于软性隐形眼镜,3 项用于角膜塑形术联合低浓度阿托品。过夜角膜塑形术试验与 2 年期间眼轴伸长减缓 0.24 至 0.32 毫米最一致。其他方式因光学设计范围广泛而更加多变。在眼镜干预中,渐进多焦点镜片效果最差,眼轴伸长和近视进展分别减缓不超过 0.11 毫米和 0.31 屈光度。相比之下,具有周边透镜的新型设计可将 2 年的伸长和进展减缓高达 0.35 毫米和 0.80 屈光度。在软性隐形眼镜干预中,中加同心双焦点仅在 3 年内减缓伸长和进展 0.07 毫米和 0.16 屈光度,而双焦点设计可在 3 年内减缓伸长和进展 0.28 毫米和 0.67 屈光度。总之,所有三种光学干预措施都有可能显著减缓近视进展。视力质量基本不受影响,安全性令人满意。不确定的领域包括治疗后进展加速的可能性以及向光学干预添加阿托品的益处。